Clearside Biomedical Files 2024 Executive Compensation Details
Ticker: CLSDQ · Form: DEF 14A · Filed: Apr 18, 2025 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | DEF 14A |
| Filed Date | Apr 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, annual-filing, equity-awards
TL;DR
Clearside Biomedical dropped its 2024 exec comp details. Check out the equity awards and dividends.
AI Summary
Clearside Biomedical, Inc. filed its DEF 14A on April 18, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted and vested during the covered year. It also reports on dividends or other earnings paid on equity awards not otherwise reflected in total compensation.
Why It Matters
This filing provides transparency into how Clearside Biomedical compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine annual filing detailing executive compensation and does not present new or unusual risks.
Key Players & Entities
- Clearside Biomedical, Inc. (company) — Filer of the DEF 14A
- 0000950170-25-055752 (filing_id) — Accession Number for the filing
- 20250418 (date) — Filing date
- 20250530 (date) — Conformed period of report
- 2024-12-31 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding Clearside Biomedical, Inc.'s executive compensation for the fiscal year ending December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 18, 2025.
What is Clearside Biomedical, Inc.'s fiscal year end?
Clearside Biomedical, Inc.'s fiscal year end is December 31.
What specific compensation elements are detailed in the filing for the covered year?
The filing details equity awards granted and vested, as well as dividends or other earnings paid on equity awards not otherwise reflected in total compensation for the covered year (2024).
What is the company's business address?
Clearside Biomedical, Inc.'s business address is 900 North Point Parkway, Suite 200, Alpharetta, GA 30005.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 18, 2025 regarding Clearside Biomedical, Inc. (CLSDQ).